Clinical Studies
利肝康 LiverPro 有益腸道
(LiverPro-001參考 Ref.: https://doi.org/10.1159/000514355 (Published online: Jan 13, 2021)
Phosphatidylcholine (PC) is intrinsically missing in intestinal mucus of patients with ulcerative colitis. LiverPro contains PC and may benefit patients with ulcerative colitis.
潰瘍性結腸炎患者腸道粘液本質上缺少磷脂酰膽鹼（PC）。 利肝康 LiverPro 含有 PC 有助腸道健康。
利肝康 LiverPro 保護使用暗瘡藥 Isotretinoin 人士的肝臟
(LiverPro-003參考Ref.: https://doi.org/10.1111/dth.13236 30 January 2020 )
Isotretinoin is for treatment severe acne (Ref: The Hong Kong Practitioner 2014;36:113-137). LiverPro can be used as an effective and low‐complication treatment for liver protection following the use of isotretinoin.
暗瘡藥異維生素 A 酸傷害肝臟(香港家庭醫學學院季刊 2014;36:113-137)。每天服用 1 粒利肝康 LiverPro 可安全有效保護異維生素 A 酸用者的肝臟
利肝康LiverPro或有助於穩定血糖
(LiverPro-004 參考Ref.: Endocrine Abstracts (2020) 70 AEP1054 )
A pilot trial in prediabetic patients with preclinical liver disease: Focus on insulin resistance 11 patients (64% women, age 49.3 ± 12.3 years, BMI 32.2 ± 6.3 kg/m2 ) with prediabetes and moderately elevated transaminases or GGT (<3 × ULN) were treated twice a day for 3 months with 2 cap of LiverPro equivalent plus Agrimonia eupatoria extract (166 mg) plus Lamium album extract (166 mg). The HOMA-2 index was significantly reduced from 3.49 ± 0.58 to 2.96 ± 0.49 (P = 0.043, paired t-test).
-
Fasting insulin was significantly reduced.
-
2 patients changed status to normoglycemia, none progressed to diabetes mellitus.
-
Liver enzymes: AST, ALT and GGT were significantly reduced.
-
There was a trend for reduced triglycerides and increased HDL-cholesterol.
-
87% compliance, no serious side effects were reported and no patient withdrew.
This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.
此產品沒有根據《藥劑業及毒藥條例》或《中醫藥條例》註冊。為此產品作出的任何聲稱亦沒有為進行該等註冊而接受評 核。此產品並不供作診斷、治療或預防任何疾病之用。
利肝康LiverPro保護蛋白尿糖尿腎病人
(LiverPro-007 參考Ref.: Renal Inj Prev 2012; 1(1):3-5. )
According to a study that evaluated prevention of progression of diabetic nephropathy, LiverPro helps protect diabetes patients with kidney problem.
根據研究利肝康有助保護蛋白尿糖尿腎病人
利肝康LiverPro或可幫助保護前列腺癌患者
(LiverPro-008 參考Ref.: European Urology Volume 48, Issue 6, December 2005, Pages 922-931 )
A study showed that LiverPro ingredient delayed PSA progression significantly. LiverPro may protect prostate cancer patients.
根據醫學研究表明，LiverPro 的成份顯著延遲了 PSA 的增加。利肝康 LiverPro 或可保護前列腺癌患者。
LiverPro 利肝康用於前列腺癌患者安全
(LiverPro – 009 參考Ref.: Investigational New Drugs volume 25, pages 139–146 (2007) )
A phase 1 and pharmacokinetic study in prostate cancer patients showed 15 cap of LiverPro daily in 3 divided doses was well tolerated in patients with advanced prostate cancer.
有前列腺癌患者的1期藥代動力學臨床研究，對於晚期前列腺癌患者，每天 15 粒 LiverPro 利肝康，分 3 次服用，似乎耐受性好。
LiverPro 利肝康對血糖和血壓高患者的代謝和血管作用的臨床研究
(LiverPro-010 參考Ref.Internal and Emergency Medicine 13 September 2018)
Metabolic & vascular effects in hypertensive patients with high 1-h post-load plasma glucose
In a study of 50 normal glucose tolerance (NGT) but 1-h post-load plasma glucose ≥ 155 mg/dl (1-h high) hypertensive insulin-resistant patients who are at higher metabolic and cardiovascular risk, LiverPro might strengthen the effect of antihypertensive drugs through improvement of the metabolic condition and further vascular protection.
有臨床研究 50 位有較高代謝和心血管風險的胰島素阻高血壓患者，其葡萄糖耐量（NGT）正 常但「飲糖水」後 1 小時血糖≥155 mg / dl，顯示 LiverPro 利肝康成份可通過改善患者的代謝狀 況和保護血管減少損傷來增強抗血壓藥的作用。
LiverPro 利肝康 可保護前列腺癌患者
(LiverPro-011 參考Ref.: BIOMEDICAL PAPERS, 2010 Sep; 154(3):239–244)
LiverPro has anti-proliferative and anti-angiogenic activities in human prostate cancer (PCa).
Low dietary selenium has been associated with increased incidence of PCa. A study showed
that LiverPro (and Selenium) might protect health after radical prostatectomy.
LiverPro 利肝康對前列腺癌細胞具有抗增殖和抗血管生增生作用。硒不足與 PCa 的發病率增加有關。研究表明 6 粒 LiverPro 利肝康 (加硒) 或有助保護前列腺患者的健康。
LiverPro利肝康 保護腎臟（可以減輕抗生素對患者腎的傷害）
(LiverPro-019 參考Ref.: Pharmaceutical Sciences, 2020, 26(3), 287-295)
According to a Randomized Double Blinded Placebo-Controlled Clinical Trial to study the protective effects of LiverPro on Gentamicin-Induced Nephrotoxicity in 60 infectious Patients, 30 patients in the treatment group and 30 in control group were given injectable GEN at least for 7 days along with total 4 capsules or placebo a day respectively.
根據一項隨機雙盲安慰劑對照臨床試驗研究60 名細菌感染患者注射慶大霉素至少 7 天，治療組和對照組各30 人同時每天分別服用 共 4 粒 LiverPro 利肝康或安慰劑。研究表明LiverPro 減低抗生素(慶大霉素)對腎的毒性。